Seqirus USA
在场
是其中之一......
CSL 是一家在股票代码 CSL (AU) 下上市的公司。
CSL 在 11 个国家有直接业务。CSL 拥有 17家子公司，其中包括 CSL Behring、CSL Behring APAC 和 CSL Behring Austria。
他们在：
高管
查看带有其 3 名主要高管的组织结构图
Seqirus USA 搜索最多的简介
- Lynette Hodgden, Global Head Enterprise Risk Management
- Rodney Lam, Director of Engineering
- Mark Faulkner, Executive Director, Sales and National Accounts
高管在CSL变化
- Elaine SorgElaine Sorg 将于20249月1作为 Independent Non-Executive Director 加入公司 (新闻发布的2024八月13号).
创建提醒
跟踪 Seqirus USA 的高管变动
药店
CSL 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
Seqirus USA 的最新新闻稿
- CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
- CSL Seqirus Announces US Government Award in Response to Avian Influenza
- News
- Seqirus Announces New Facility Supporting Research and Development of Influenza Vaccine Technology
- CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older
- Update on CDC Advisory Committee Immunization Practices Review Enhanced Flu Vaccines Adults 65 plus
- CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
- CSL Seqirus to Highlight Commitment to Influenza Protection with Data Presentations at OPTIONS XI
- CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
- CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine
- View more press releases Close
关于 Seqirus USA 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Rodney Lam 
